ACADIA Pharmaceuticals Inc. $ACAD Shares Bought by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC increased its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 25.4% in the fourth quarter, now owning 658,813 shares valued at $17.32 million. ACADIA surpassed quarterly earnings expectations with an EPS of $1.60 and revenue of $298 million, showing a 9.4% year-over-year growth. Analysts maintain a generally positive outlook, with Mizuho upgrading the stock to "outperform" and a consensus price target of $31.21.
ACAD PE Ratio & Valuation, Is ACAD Overvalued
ACADIA Pharmaceuticals Inc (ACAD) is currently considered undervalued, with a fair price estimated between $31.14 and $50.32 compared to its current price of $22.20. Its current forward P/S ratio of 2.72 is significantly below its five-year average, and its P/B ratio is also lower than its historical averages. Despite these metrics suggesting undervaluation, the article notes that ACAD's P/S ratio is still above the industry average, questioning its sustainability given its revenue growth.
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts
This article is a placeholder for ACADIA Pharmaceuticals Inc. (ACAD) stock forecasts. It appears to be part of a larger Yahoo Finance platform, containing various navigation links and sections related to financial markets and news. However, the core content for the stock forecast is missing due to a data retrieval error.
Insiders At ACADIA Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness
Over the past year, ACADIA Pharmaceuticals (NASDAQ:ACAD) insiders sold US$1.0 million worth of stock, primarily a US$671,000 sale by Independent Director James Daly at approximately US$22.37 per share. While insider selling can have multiple interpretations, multiple sales over a period may signal potential weakness. Despite these sales, insiders still own 0.6% of the company, valued at about US$22 million, which suggests some alignment with shareholder interests.
Glioblastoma Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics, Autotelic Therapeuti
DelveInsight's "Glioblastoma Pipeline Insight, 2026" report highlights that over 200 companies are actively developing more than 220 Glioblastoma treatment therapies. The report provides a deep dive into the commercial and clinical assessment of these pipeline products, covering drug mechanisms, clinical studies, and development activities. Key companies and emerging therapies like Enzastaurin and SurVaxM are discussed, alongside recent clinical trial updates and strategic collaborations aimed at advancing Glioblastoma treatment.
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral Rating
BofA Securities has increased its price target for ACADIA Pharmaceuticals Inc. (ACAD) to $23 while maintaining a Neutral rating on the company's stock. This adjustment reflects the firm's updated valuation of ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has received a "Moderate Buy" consensus rating from twenty brokerages, with an average one-year target price of $31.21. The biopharmaceutical company recently reported strong quarterly earnings, beating EPS estimates significantly and showing a 9.4% year-over-year revenue increase. The article also notes insider selling by an EVP and significant institutional investment activity in the company.
Acadia EVP Thompson sells $73k in stock after option exercise
Elizabeth H.Z. Thompson, an Executive Vice President at ACADIA PHARMACEUTICALS INC, sold 3,435 shares of company stock for approximately $73,749 after exercising options for 6,715 shares. The sale leaves Thompson with 3,280 directly owned shares. This transaction follows other recent news for Acadia, including an upgrade from BofA Securities and a negative opinion from the European Medicines Agency regarding one of its treatments.
Acadia Pharma EVP Schneyer sells $159k in stock
Acadia Pharmaceuticals' EVP and CFO, Mark C. Schneyer, sold 7,385 shares of company stock for approximately $159,135 to cover tax obligations related to vested restricted stock units. This occurred shortly after he acquired 14,316 shares through similar vestings. The company recently saw BofA Securities upgrade its rating to Buy despite a lowered price target due to pipeline review and an EU regulatory setback for its drug trofinetide.
ACADIA (NASDAQ: ACAD) officer sells 1,942 shares after RSU vesting
James Kihara, the principal accounting officer for ACADIA PHARMACEUTICALS INC. (NASDAQ: ACAD), sold 1,942 shares of common stock between March 24-26, 2026, to cover withholding taxes related to restricted stock unit (RSU) vesting. He exercised or converted 3,769 RSUs into common stock. After these transactions, Kihara directly holds 26,885 shares of common stock and 4,883 restricted stock units.
ACADIA Pharmaceuticals (NASDAQ: ACAD) — Vanguard reports 0 shares in amendment
The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A, reporting that it beneficially owns 0 shares of ACADIA Pharmaceuticals Inc. common stock, representing 0% of the class. This change reflects an internal realignment and the disaggregated reporting of certain Vanguard subsidiaries, in accordance with SEC Release No. 34-39538 (January 12, 1998). This is a procedural reporting change, not a transaction, and stakeholders should look for future filings from individual Vanguard subsidiaries for ownership details.
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Mixed Share Performance
ACADIA Pharmaceuticals (ACAD) has shown mixed share performance recently, despite longer-term gains for shareholders. The company is currently valued at US$21.47, with a market value of about US$3.8 billion, and generates significant revenue and net income from its neurology medicines. A key narrative suggests ACADIA is 25.3% undervalued, with a fair value of $28.75 per share, though this hinges on successful clinical execution and regulatory outcomes.
Acadia Pharma CEO Owen Adams Catherine sells $249k in stock
Acadia Pharmaceuticals CEO Owen Adams Catherine sold 11,641 shares of company stock for approximately $249,932 on March 25, 2026. This transaction followed the exercise of Restricted Stock Units and leaves the CEO with 14,803 directly owned shares. The company's stock has been down about 20% year-to-date but gained 25% over the past year, and it is considered undervalued by InvestingPro analysis.
Acadia Pharma EVP Schneyer sells $159k in stock
Acadia Pharmaceuticals' EVP and CFO Mark C. Schneyer sold 7,385 shares of company stock for approximately $159,135 to cover tax obligations related to restricted stock unit vesting. Simultaneously, Schneyer acquired 14,316 shares through vested units. The company has recently faced a negative opinion from the European Medicines Agency regarding its drug trofinetide, while BofA Securities updated its rating and price target for the stock.
Acadia Pharmaceuticals exec sells $41,895 in stock
James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals Inc (NASDAQ:ACAD), sold 1,942 shares of company stock worth $41,895 to cover withholding taxes. This comes alongside recent analyst upgrades by BofA Securities and news of the company's Q4 earnings, new board appointments, and a negative opinion from the European Medicines Agency regarding its trofinetide application.
ACADIA (ACAD) CLO exercises RSUs and sells shares to cover taxes
Jennifer J. Rhodes, EVP and Chief Legal Officer of ACADIA Pharmaceuticals (ACAD), exercised 7,515 restricted stock units into common shares. The following day, she sold 3,844 common shares at $21.47 each. These mandatory sales were made to cover withholding taxes related to the RSU vesting, in compliance with Rule 10b5-1(c).
ACADIA (NASDAQ: ACAD) EVP covers taxes with share sale and RSU vesting
ACADIA Pharmaceuticals EVP Elizabeth H.Z. Thompson reported routine equity compensation activity, including the vesting of 6,715 restricted stock units on March 24, 2026. On March 25, 2026, she sold 3,435 shares at $21.47 each to cover withholding taxes, as part of a Rule 10b5-1 arrangement. Following these transactions, Thompson directly holds 3,280 common shares and 20,146 restricted stock units.
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Mixed Share Performance
ACADIA Pharmaceuticals (ACAD) has experienced mixed share performance recently, with short-term weakness but long-term gains for shareholders. Despite this, a common valuation narrative suggests the stock is undervalued at $28.75 per share compared to its current price of $21.47, reflecting market caution regarding pipeline expansion and long-term growth. The article suggests investors should independently review the financials, as the undervalued status depends on clinical execution and regulatory outcomes.
Acadia Pharmaceuticals stock price forecast: overbought conditions persist as ACAD closes near key resistance
Acadia Pharmaceuticals (ACAD) saw a significant 6.12% increase over the past week, closing near its weekly high, and jumped 5.01% intraday. Despite this short-term bullish sentiment, mixed momentum indicators and weak trend strength suggest that the stock is overbought. Analysts predict consolidation between $21.97 support and $22.62 resistance, with a pullback being more likely than a sustained breakout next week.
This General Motors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Wolfe Research upgraded General Motors (NYSE: GM) to Outperform with a $96 price target. Other analyst upgrades include Murphy Oil (NYSE: MUR) by Johnson Rice, Enterprise Products Partners (NYSE: EPD) by Wells Fargo, ACADIA Pharmaceuticals (NASDAQ: ACAD) by B of A Securities, and CVR Energy (NYSE: CVI) by Raymond James. These upgrades reflect positive shifts in outlook for these companies.
ACADIA Pharmaceuticals Shares Rise After BofA Upgrade
ACADIA Pharmaceuticals' shares saw an increase after BofA Global Research upgraded the stock rating from "Neutral" to "Buy." The upgrade is attributed to the company's strong commercial execution of its drug Nuplazid, which addresses unmet needs in Parkinson's disease psychosis. BofA also anticipates positive clinical data for trofinetide in Rett syndrome, which could further boost ACADIA's market position.
Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback
Bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to 'Buy' from 'Neutral', maintaining a $29 price objective. The upgrade reflects an improved risk-reward profile following a recent 25% stock decline, which analysts attribute to macro factors rather than fundamental issues. The firm highlights the stable sales of Acadia's Parkinson's disease psychosis drug Nuplazid and an underappreciated pipeline, particularly remlifanserin for Alzheimer’s disease psychosis, as key drivers for potential upside.
Acadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback
BofA analyst Tazeen Ahmad has upgraded Acadia Pharmaceuticals (ACAD) to a Buy rating from Neutral, maintaining a $29 price target. The upgrade follows a 25% pullback in the stock, which the analyst attributes to macro factors rather than fundamental issues. BofA projects Nuplazid sales to reach $888 million by 2029 and sees an $11 billion pipeline opportunity for the company.
ACAD: B of A Securities Upgrades ACADIA Pharmaceuticals Rating to Buy | ACAD Stock News
B of A Securities has upgraded ACADIA Pharmaceuticals (ACAD) from a "Neutral" to a "Buy" rating, maintaining a $29.00 USD price target. This upgrade comes amidst varying analyst ratings over the past months, with an average target price from 19 analysts at $31.74, implying a 51.42% upside from its current price. Acadia Pharmaceuticals is focused on developing medicines for CNS disorders and rare diseases, with key commercial products NUPLAZID and DAYBUE.
ACADIA Pharmaceuticals (NASDAQ:ACAD) Raised to "Buy" at Bank of America
Bank of America upgraded ACADIA Pharmaceuticals (NASDAQ:ACAD) to a "Buy" rating with a $29 price target, citing a potential upside of 38.36%. This follows a strong quarter where ACADIA beat earnings and revenue estimates, reporting $1.60 EPS and $298 million in revenue. The company currently holds a "Moderate Buy" consensus rating among analysts with an average price target of $31.21.
Acadia Pharma upgraded at BofA following stock pullback
BofA Securities has upgraded Acadia Pharmaceuticals (ACAD) from neutral to buy. This upgrade follows a 25% stock pullback, with BofA indicating that the company's fundamentals remain strong despite macro-driven market downturns seen since the beginning of the year.
Hudson Bay Capital Management LP Sells 119,700 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Hudson Bay Capital Management LP significantly reduced its stake in ACADIA Pharmaceuticals Inc. ($ACAD) by selling 119,700 shares, bringing its total holdings to 70,300 shares valued at $1.5 million. This occurred despite several other major institutional investors, including Braidwell LP and Millennium Management LLC, initiating or increasing substantial positions in the company, leading to 96.71% institutional ownership. ACADIA Pharmaceuticals recently outperformed quarterly earnings estimates and analysts maintain a "Moderate Buy" rating with an average price target of $31.21.
ACADIA (NASDAQ: ACAD) director Jonathan Poole submits initial Form 3 insider report
Jonathan Poole, a director at ACADIA PHARMACEUTICALS INC (NASDAQ: ACAD), has filed an initial Statement of Beneficial Ownership (Form 3). This filing signifies his official status as a director for SEC insider reporting purposes but does not involve any stock transactions, purchases, or sales. The Form 3 details his directorship and confirms no beneficial ownership of non-derivative or derivative securities at the time of the filing.
Acadia (NASDAQ: ACAD) director receives new option and RSU awards
Acadia Pharmaceuticals director Jonathan Poole received new equity awards on March 3, 2026, as part of his compensation. These awards include 7,482 stock options and an additional 3,565 options, each with a $22.50 exercise price, alongside 4,218 and 2,010 restricted stock units. The equity awards have varying vesting schedules, primarily over one to three years, with some vesting tied to the next annual stockholder meeting.
Wolfe Research notes conviction-driven opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) therapeutic domains
Wolfe Research highlighted conviction-driven opportunities in ACADIA Pharmaceuticals Inc.'s therapeutic areas, specifically focusing on the company's leading product, NUPLAZID. The research note indicated high confidence in the growth prospects of NUPLAZID for Parkinson’s Disease Psychosis and anticipated its broader application to treat symptoms in Alzheimer’s Disease Psychosis. This suggests a strong outlook for ACAD's pipeline and market expansion.
ACADIA Pharmaceuticals invites engagement at major pediatric event
ACADIA Pharmaceuticals is participating in the 47th National Conference on Pediatric Health Care, where it will share data on Rett syndrome and information on ongoing research. This engagement highlights the company's continuous efforts to advance research in central nervous system disorders and raise awareness for rare pediatric diseases. ACADIA's presence at this event follows its recent participation in the Stifel 2026 Virtual CNS Forum and the Baltimore genetics meeting.
Algert Global LLC Has $8.54 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD
Algert Global LLC significantly increased its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 653.6% in the third quarter, now owning 400,109 shares valued at $8.54 million. Other institutional investors also raised their positions, with 96.71% of the stock owned by institutional investors. ACADIA Pharmaceuticals reported strong quarterly earnings, beating analyst estimates, and analysts have a "Moderate Buy" consensus rating with an average price target of $31.21.
ACADIA Pharmaceuticals (ACAD) Is Down 5.3% After EMA Rejects Trofinetide In Rett Review - What's Changed
ACADIA Pharmaceuticals (ACAD) saw a 5.3% drop after the EMA's CHMP issued a negative opinion on its marketing application for trofinetide in Rett syndrome, despite also appointing a new biopharma finance executive to its board. This regulatory setback in Europe challenges the company's previous Rett-focused investment narrative and near-term European expansion plans. While the U.S. DAYBUE franchise and 2026 revenue guidance remain key, analysts are re-evaluating revenue and earnings forecasts, with some expecting slower international growth and increased focus on NUPLAZID concentration risk.
ACADIA Pharmaceuticals (ACAD) Is Down 5.3% After EMA Rejects Trofinetide In Rett Review - What's Changed
ACADIA Pharmaceuticals faced a 5.3% drop after the EMA's CHMP issued a negative opinion on its trofinetide marketing application for Rett syndrome in Europe, despite the company appointing a new biopharma finance executive to its board. This regulatory setback challenges ACADIA’s European expansion plans for trofinetide, though its U.S. DAYBUE franchise and 2026 revenue guidance remain key short-term focuses. The company's investment narrative now hinges on its existing commercial products, NUPLAZID and DAYBUE, and how new board expertise will navigate balancing R&D spend with cash generation.
Acadia Pharmaceuticals annual revenue surpasses 1 billion dollars at Nasdaq bell ceremony
Acadia Pharmaceuticals has achieved a significant milestone, surpassing 1 billion dollars in annual revenue for the first time. This accomplishment was celebrated with the ringing of the Opening Bell at the Nasdaq Exchange, highlighting the company's commitment to advancing the pharmaceutical sector. Acadia's success is attributed to its strategic engagements and continued progress in transforming scientific innovations into new therapies.
Acadia Pharmaceuticals Rings the Nasdaq Stock Market Opening Bell
Acadia Pharmaceuticals (NASDAQ: ACAD), a biopharmaceutical company focused on neurological and rare diseases, visited the Nasdaq MarketSite in Times Square. The company's CEO, Catherine Owen Adams, rang the Nasdaq Stock Market Opening Bell to commemorate the occasion. This event is part of Nasdaq's daily tradition of market open and close ceremonies.
Fred Alger Management LLC Sells 820,421 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Fred Alger Management LLC has reduced its stake in ACADIA Pharmaceuticals Inc. by 34.4%, selling 820,421 shares and now holding 1,567,035 shares valued at $33.44 million. Despite this, other institutions like Braidwell LP, Marshall Wace LLP, and Arrowstreet Capital Limited Partnership have significantly increased their holdings, pushing institutional ownership to 96.71%. ACADIA recently reported strong Q3 earnings, exceeding analyst expectations, and maintains a "Moderate Buy" consensus rating among analysts with a target price of $31.21.
Braidwell LP Makes New $50.76 Million Investment in ACADIA Pharmaceuticals Inc. $ACAD
Braidwell LP has made a new investment of $50.76 million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by purchasing 2,378,655 shares in the third quarter, making it their 24th largest holding. Other institutional investors also adjusted their stakes in ACADIA, with hedge funds and institutional investors collectively owning 96.71% of the company's stock. Analysts generally have a "Moderate Buy" rating for ACADIA Pharmaceuticals, with a consensus price target of $31.21.
CNBC Cures: Acadia Pharmaceuticals CEO on scaling rare and neuro-focused drugs
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's commitment to patients with underserved neurological and rare diseases. She provides insights into their relationship with the FDA and the prospects for their drug development pipeline. The interview took place on CNBC's Squawk Box.
Has ACADIA Pharmaceuticals (ACAD) Pullback Opened A New Opportunity For Investors?
ACADIA Pharmaceuticals (ACAD) has experienced recent stock price declines but appears undervalued based on two valuation approaches. A Discounted Cash Flow (DCF) analysis suggests the stock is 86.0% undervalued, while its Price-to-Earnings (P/E) ratio is significantly below the industry average. The article also presents bullish and bearish narratives for the company, offering different perspectives on its fair value.
Has ACADIA Pharmaceuticals (ACAD) Pullback Opened A New Opportunity For Investors?
ACADIA Pharmaceuticals' stock has seen recent pullbacks, with a 7% decline over the last week, despite a 17.8% return over the past year. Simply Wall St's analysis suggests the stock is significantly undervalued, with a Discounted Cash Flow (DCF) model indicating it is 86.0% undervalued and its P/E ratio also below industry and peer averages. The article presents bullish and bearish narratives to help investors evaluate the potential future value of ACADIA Pharmaceuticals, considering factors like product portfolio, pipeline developments, and pricing power.
ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by First Trust Advisors LP
First Trust Advisors LP significantly reduced its stake in ACADIA Pharmaceuticals Inc. by 20.2% in the third quarter, selling 491,224 shares, though it still holds 1.94 million shares valued at $41.47 million. This comes as ACADIA Pharmaceuticals reported strong quarterly earnings, beating expectations with an EPS of $1.60 and revenue of $298 million. Despite some share selling by institutional investors and an EVP, analysts maintain a "Moderate Buy" rating with an average price target of $31.21, and UBS raising its target to $40.
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors By Investing.com
Acadia Pharmaceuticals has appointed Jonathan M. Poole to its board of directors and audit committee, effective immediately. Mr. Poole will receive annual cash retainers and equity awards, with vesting contingent on his continued service to the company. This announcement follows mixed analyst perspectives due to the European Medicines Agency's negative opinion on trofinetide for Rett syndrome, though some analysts raised price targets based on other product growth.
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Acadia Pharmaceuticals Inc. announced its participation in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026, at 8:00 a.m. Eastern Time. A live webcast and archived recording will be available on the company's investor relations website. The company specializes in treatments for neurological and rare diseases, including FDA-approved therapies for Parkinson’s disease psychosis and Rett syndrome.
Acadia Pharmaceuticals (ACAD) grants CEO large options and RSUs
Acadia Pharmaceuticals Inc. (ACAD) has granted its CEO, Owen Adams Catherine, new equity awards as compensation. She received 263,005 stock options with an exercise price of $22.16 and 76,509 restricted stock units, both subject to multi-year vesting schedules. These grants are part of her compensation package and do not represent open-market purchases or sales.
Acadia (NASDAQ: ACAD) EVP awarded large stock option and RSU grants
Acadia Pharmaceuticals Inc. EVP Elizabeth H.Z. Thompson was granted significant equity awards, including a stock option for 101,574 shares at an exercise price of $22.16 and 29,548 restricted stock units. These awards have specific vesting schedules, with the stock options vesting over more than three years and RSUs vesting in four equal annual installments starting March 6, 2027. This information was disclosed in a Form 4 SEC filing, indicating insider trading activity.
ACADIA Pharmaceuticals to exhibit at ACMG event in Baltimore
ACADIA Pharmaceuticals announced its participation in the Annual Clinical Genetics Meeting hosted by the American College of Medical Genetics and Genomics in Baltimore, Maryland. The company will have two booths at the event to engage with industry professionals and expects to connect with experts in clinical genetics. Attendees are invited to visit their booths for more details.
Neo Ivy Capital Management Buys Shares of 62,568 ACADIA Pharmaceuticals Inc. $ACAD
Neo Ivy Capital Management acquired 62,568 shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in Q3, valued at approximately $1.335 million. ACADIA exceeded Q3 earnings estimates with EPS of $1.60 and revenue of $298 million. The stock holds a "Moderate Buy" consensus rating with an average target price of $31.21 from analysts.
ACADIA Pharmaceuticals (ACAD) Valuation After CHMP Setback On Trofinetide For Rett Syndrome
ACADIA Pharmaceuticals (ACAD) shares reacted to a formal negative opinion from the EU’s CHMP regarding trofinetide for Rett syndrome, introducing uncertainty about potential European revenue. Despite recent share price declines, the company reported significant revenue and net income, with a narrative fair value suggesting it is 29% undervalued. The outlook hinges on the success of its diverse pipeline and market conditions for its existing products.
ACADIA Pharmaceuticals (ACAD) Valuation After CHMP Setback On Trofinetide For Rett Syndrome
ACADIA Pharmaceuticals (ACAD) recently faced a setback following a negative opinion from the EU’s CHMP regarding trofinetide for Rett syndrome, leading to renewed uncertainty for its potential European revenue. Despite a recent decline in share price, the company's long-term shareholder returns remain positive. This article evaluates ACADIA's valuation, considering its pipeline momentum and the market's perception of its future growth, suggesting it may be undervalued.
